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Kidney transplantation is the preferred modality of renal replacement therapy.  Long-term 
patient- and graft- survival have only improved marginally over the recent decade, mainly 
due to the development of cardiovascular disease following transplantation.  Obesity is a risk 
factor for cardiovascular disease, and is common pre- and post- transplantation.  This article 
reviews the literature assessing the role of pre- and post- transplant obesity on patient- and 
graft- survival, discusses the underlying obesity-related mechanisms leading to inferior 
kidney transplant outcomes, and explores the role of nutritional intervention on improving 
long-term outcomes of transplantation.  While the role of pre-transplant obesity remains 
uncertain, post-transplant obesity increases the risk of graft failure and mortality.  Nutritional 
intervention is effective in achieving post-transplant weight loss, but the impact on long-term 
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outcomes has not been established.  Future research should focus on conducting nutritional 









Kidney transplantation is the preferred modality of renal replacement therapy for many 
patients with end-stage renal disease (ESRD) 1.  Compared to remaining on transplant waiting 
list, kidney transplantation improves long-term survival 2, enhances quality of life 3, 
demonstrates cost benefit 4, and rectifies uraemia and metabolic abnormalities contributing to 
overall sense of well-being 5.  Despite several advantages following successful 
transplantation, the corollary of the current shortage of organs is that only a proportion of 
patients on transplant waiting list proceed to transplantation, with up to 40% dying whilst 
waiting on dialysis 6.  It is crucial that the best possible use is made of those transplanted 
kidney (graft), and therefore optimising patient- and graft- survival following transplantation 
should be a priority in this patient group. 
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Short-term patient- and graft- survival have substantially improved over the recent decades, 
with most centres reporting both survival rates at 1 year of greater than 90% 7.  However, 
long-term success has been difficult to accomplish as evident by the marginal increase in 
patient- and graft- survival rates over the past 15 years 8.  This phenomenon is multifactorial.  
Firstly, modification of alloimmunity using immunosuppression has reduced short-term early 
acute rejection rates 8, but the nephrotoxicity of immunosuppressive medication is known to 
limit long-term graft survival 9.  Secondly, the use of maintenance immunosuppressive 
therapy is associated with increased risk of infection and malignancy 10.  Thirdly, 
cardiovascular disease (CVD) is a well-known long-term complication in kidney transplant 
recipients (KTRs) 11.  It is both the leading cause of death following transplantation 12 and 
death with a functioning graft 13. 
 
According to the World Health Organization, overweight is defined as a BMI of 25.0 to 29.9 
kg/m2; and obesity is defined as a BMI of ≥ 30.0 kg/m2 14.  Prior to transplantation, the role of 
obesity on long-term patient- and graft survival remains uncertain.  However, available 
evidence suggests that obesity predisposes to delayed graft function with subsequent impact 
on graft failure 7.  Following transplantation, obesity is strongly associated with reduced 
long-term patient- and graft survival 7, but it failed to display an independent relationship 
with CVD risk 15-18.  However, obesity leads to higher prevalence of CVD risk factors 
including hypertension, dyslipidaemia, diabetes mellitus and insulin resistance, all of which 
are independently associated with increased risk of graft failure 15-18.  These individual 
diseases also cluster as part of metabolic syndrome.  A recent sub-analysis of the ALERT 
(Assessment of LEscol in Renal Transplantation) study revealed that metabolic syndrome 
was associated with increased risk of graft failure 19.  Obesity is modifiable by nutritional 
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intervention, but the impact of weight loss resulting from these interventions on long-term 
patient- and graft- survival has not been well-established.   
 
The purposes of this article were to review the relevant literature assessing the role of pre- 
and post- transplant obesity on patient- and graft- survival, to discuss the potential underlying 
mechanisms by which obesity induces its detrimental effects leading to inferior kidney 
transplant outcomes, and to explore the role of nutritional intervention on improving long-
term outcomes of kidney transplantation.  Finally, this article aims to identify gaps in current 
literature and recommends potential areas for future research.  
 
Prevalence and impact of obesity prior to transplantation 
 
Overweight and obesity are common at the time of transplantation 20.  Currently, 60% of 
KTRs are overweight at the time of transplantation, representing a 116% increase from 1987 
20.  Indeed, many transplant centres in the UK and US exclude patients with a BMI greater 
than 30 or 35 kg/m2 21.  A BMI ≥ 35 kg/m2 was the third most common reason to exclude as 
many as 10% of patients from transplantation 22.  Despite this, the effect of pre-transplant 
obesity on patient- and graft- survival remains controversial, with several conflicting studies 
in the literature.  Table 1 summarises the studies examining the impact of pre-transplant 
obesity on kidney transplant outcomes.  In some studies, while pre-transplant obesity had no 
effect on long-term outcomes, it demonstrated a negative impact upon short-term outcomes 
including graft failure within the first year post-transplant 23, post-transplant surgical 
complications and delayed graft function 24-29.  Despite the lack of relationship between pre-
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transplant obesity and long-term outcomes in these studies, it is important to note that 
delayed graft function is associated with reduced long-term graft survival 7,30.  Some studies 
showed that obesity exerts a negative impact on long-term patient- and graft survival 7,31-36.  
In contrast, adverse impact of obesity on both short- and long- term outcomes were seen in 
some studies 31,33.  Also, a study by Yamamoto et al 35 otherwise demonstrated that while 
obesity had no effect on short-term graft survival, decreased medium- and long- term graft 
survival were observed in obese KTRs.  Finally, Streja et al showed that obesity was 
associated with graft loss, but had no effect on mortality 36.  In summary, studies with short-
term outcome data have unanimously demonstrated negative impact of pre-transplant obesity 
whilst studies with long-term outcome data have yielded variable conclusions.  Such 
conflicting results from the latter group of studies may partly stem from large variations in 
the sample size and follow-up period (2-20 years), with studies of larger sample size and ≥6-
year follow-up generally showing an impact.  
 
Impact of body composition prior to transplantation 
 
Given the conflicting data on the effect of pre-transplant obesity on patient- and graft- 
survival, a recent study explored the effect of body composition on long-term patient- and 
graft- survival rates.  It showed that sarcopenic obesity prior to transplantation was associated 
with increased mortality and graft failure 36, while sarcopenia in the study was defined as 
reduced pre-transplant muscle mass represented by lower pre-transplant serum creatinine in 
patients with BMI ≥ 30 kg/m2. 
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Impact of weight loss during transplant listing 
 
Whilst the effect of pre-transplant obesity on patient- and graft- survival remains unclear, 
Schold et al reported that weight loss during transplant listing had no effect on long term 
outcomes following transplantation including mortality risk and graft loss across the entire 
BMI spectrum 37.  The same study also highlighted that substantial weight loss pre-transplant 
was associated with rapid weight gain following transplantation 37.  This finding, together 
with the observed “obesity paradox” in the dialysis population 38, suggest that weight loss 
prior to transplantation may not necessarily be beneficial, as mortality risk during transplant 
listing and following transplantation is not alleviated.  However, the authors highlighted that 
these information needs to be interpreted with caution as data on BMI was taken from the 
registry and crucial information including the nature of weight change and other aspects of 
nutritional status is therefore unavailable 37.  Intentional weight loss that is potentially 
beneficial may be masked by weight loss that is a manifestation of malnutrition or 
progressive disease 37. 
 
In addition, a retrospective study of the United States Renal Data System (USRDS) registry 
found that substantial weight loss was achieved with bariatric surgery in a cohort of patients 
prior to transplant-listing and wait-listed for transplantation 39.  These results were similar to 
findings from recent studies, which demonstrated that laparoscopic Roux-en-Y gastric bypass 
and laparoscopic sleeve gastrectomy were effective procedures for weight loss and improved 
candidacy for kidney transplantation 40,41.  However, perioperative complications and 
mortality within a 30-day period post bariatric surgery were evident 39,41.  Also, the impact of 
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intentional weight loss induced by bariatric surgery on short- and long- term patient- and 
graft- survival has not yet been examined. 
 
Prevalence and causes of obesity following transplantation  
 
Weight gain following transplantation is very common and occurs in up to 50% of KTRs 42,43, 
affecting both obese and non-obese patients 44.   The average weight gain following 
transplantation is between 10% and 35% of body weight, with the majority of weight gain 
within the first 12 months following transplantation 42,45-47.  Much of the weight gain post-
transplant is attributed to an increase in body fat mass, especially in the abdominal area 48,49. 
 
Excessive weight gain and increased fat mass in KTRs is traditionally attributed to the 
immunosuppression treatment protocol post-transplantation.  This is due to the well-known 
hyperphagic effect of steroids, and its adverse influence on adipocytes, resting energy 
expenditure and lipid oxidation, resulting in centripetal obesity i.e. increased fat deposition in 
the peritoneum, mediastinum, subcutaneous sites such as face and neck 49.  However, recent 
evidence suggests that the effect of steroids on weight gain is controversial.  Table 2 
summarises the studies showing the impact of steroids on weight gain and body composition.  
First of all, an early study by Ratcliffe et al 50 showed that KTRs on steroid withdrawal 
therapy achieved a significant reduction in body weight compared to steroid maintenance 
therapy.  Another study by van den Ham et al 49 indicated that weight gain after the first year 
post-transplant was significantly and positively related to cumulative steroid dose.  Further 
studies by Rogers et al 51 and Woodle et al 52  showed that early steroid withdrawal 
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minimizes weight gain in KTRs.  However, contrasting studies proposed that the role of 
steroid use on post-transplant weight gain is only partial as an increase in body weight was 
seen in all KTRs regardless of the immunosuppression protocol 42,49,53.  In particular, Elster et 
al 53 reported no significant difference in weight gain between patients treated with steroid 
and patients on steroid avoidance therapy, and Johnson et al 42 found no correlation between 
weight gain and cumulative steroid dose, which in part is similar to findings from van den 
Ham et al 49 where weight gain in the first year post transplant was related neither to 
maintenance nor to cumulative steroid dose.  Furthermore, a single centre study showed no 
difference in fat mass between steroid avoidance and steroid maintenance protocols, and no 
relationship was observed between cumulative steroid dose and body composition 54. 
 
While the effect of immunosuppressive protocol on weight gain and changes in body 
composition is controversial, other contributing factors for post-transplant weight gain should 
be considered.  Age, gender, ethnicity, pre-transplant BMI, dialysis modality, the occurrence 
and treatment of rejection, and graft function have all been suggested as significant 
contributors to weight changes following transplantation 42,45,49.  Importantly, weight gain 
post transplantation may be largely due to lifting of previous dietary restrictions, improved 
appetite following the correction of uraemia, and enhanced sense of well-being that occurs 
with transplantation.  
 
Impact of obesity following transplantation 
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Irrespective of the contributing factors to post-transplant weight gain, obesity following 
transplantation is known to adversely affect cardiovascular risk profile and graft function 55.  
A recent study by Hoogeveen et al 7 showed that one year following transplant, BMI and 
BMI increments were both significant risk factors for mortality and graft failure in the long-
term.  In contrast, Kovesdy et al 56  reported that higher BMI was associated with lower 
mortality after adjustment for waist circumference, whereas higher waist circumference was 
associated with higher mortality after adjustment for BMI.  The opposite association 
displayed by BMI and waist circumference highlighted the uncertainty of relying on BMI as a 
marker of obesity in view of its incapability to distinguish between visceral adiposity, 
subcutaneous adiposity and muscle mass.  Additionally, clinically obese patients with 
exclusive subcutaneous fat excess were found in a normal metabolic state and demonstrated a 
limited deposition of fat at visceral sites 57, conferring to reduced metabolic risk.  These 
findings suggest that not only waist circumference appears to be a better prognostic marker 
for obesity than BMI, visceral adiposity adversely affect kidney transplant outcomes, and 
increased subcutaneous fat and/or muscle mass may be protective against mortality risk.  In 
addition, recent data from a renal transplant population showed that lower urinary creatinine 
excretion, a proxy for reduced muscle mass, was associated with increased mortality and 
graft failure 58. 
 
Obesity-related mechanisms of inferior kidney transplant outcomes 
 
A number of mechanisms associating obesity and inferior transplant outcomes have been 
proposed, these are summarised in Figure 1.  Overall, sarcopenic obesity, characterised by 
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reduced muscle mass coupled with increased fat mass, appears to be the driving force behind 
these mechanisms.   
 
A link between muscle mass and survival has been suggested, increased muscle mass has 
been proposed to improve skeletal, respiratory and cardiac muscle function, and  
consequently improve muscle-based oxidative mechanism leading to increased antioxidant 
defence 56.  Reduced muscle mass may therefore exerts a negative effect on the proposed 
mechanism, leading to increased risk of cardiovascular disease, cancer, neurodegenerative 
disorders, and other chronic conditions 59.  Also, gelsolin produced by the skeletal muscle has 
been shown to be associated with improved survival in dialysis patients 56.  Although the 
effect of gelsolin has not been studied in kidney transplantation, the depletion of which may 
explain the higher mortality risk in KTRs.    
 
Negative metabolic effects of raised BMI and adiposity, particularly visceral adiposity, may 
explain the increased CVD risk and graft failure observed in KTRs.  First of all, the ALERT 
trial showed that raised BMI was associated with inflammation 60, where inflammatory  
markers including interleukin-6 (IL-6) and high-sensitivity c-reactive protein (hsCRP) were 
independently and positively associated with major cardiovascular events and all-cause 
mortality in KTRs 60.  Specifically, visceral adipose tissue is the most metabolically active 
system that secretes adipokines (cytokines secreted by adipose tissue), examples include 
chemerin, IL-6, visfatin, adiponectin, leptin, tumor-necrosis factor-α (TNF-α), and resistin 61.  
The role of adipokine has received preliminary attention in kidney transplantation.  Kaisar et 
al found that adiponectin (an adipokine) up-regulates high-density lipoprotein (HDL) and 
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down-regulates triglycerides in KTRs, a typical profile of dyslipidaemia associated with 
obesity 62,57, and confers to increased CVD risk in KTRs62.  However, Chitalia et al found no 
association between adiponectin and CVD risk in kidney transplant population 63.  
Nevertheless, adiponectin was shown to correlate inversely with inflammation in KTRs,  
characterised by elevated c-reactive protein (CRP) 62.  In addition, elevated levels of visfatin 
were found to correlate with inflammation and markers of endothelial damage in KTRs, 
including raised levels of hsCRP, prothrombin fragments 1 + 2, and vascular cell adhesion 
molecule (VCAM) 64.  Furthermore, raised resistin levels correlated with markers of 
inflammation and endothelial dysfunction in KTRs, including elevated levels of hsCRP, IL-6, 
thrombomodulin and VCAM 65.   
 
The link between inflammation and mortality in KTRs has been established by Winkelmayer 
et al 66.  Inflammation has been proposed to exert its downstream adverse sequelae via the 
mediation of vascular damage causing vascular inflammation, which in turn leads to 
pathogenesis of atherosclerosis in KTRs 60.  Another suggested mechanism associated with 
adiposity is that adipose tissues secretes pro-inflammatory cytokines including TNF-α and 
IL-6, which sequentially activates renin-angiotensin-aldosterone pathway, contributing to the 
onset and progression of graft damage by sustaining cell growth, inflammation and fibrosis 7. 
 
In addition, the metabolic load of the graft increases as a result of obesity, the graft 
consequently adapt by increasing in size and glomerular filtration 7.  The combining effect of 
fibrosis and glomerulomegaly are the most common histologic lesions in patients with 
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obesity-related glomerulopathy, suggesting that these are important pathways leading to graft 
failure 7.   
 
Obesity intervention strategies 
 
Lifestyle modification and behavioural intervention 
 
Currently, no interventional studies exist to evaluate the effect of pre-transplant obesity 
management on long-term clinical outcomes of kidney transplantation.  It is unsurprising as 
the effect of pre-transplant obesity on kidney transplant outcomes remains uncertain.  In 
contrast, 4 studies have evaluated the effect of lifestyle interventions on weight management 
post transplantation, with all studies consistently demonstrated that nutritional interventions 
were effective in achieving weight loss, as summarised in Table 3.  It is worth noting that 
lifestyle intervention incorporating dietary advice led to improved CVD risk factors in KTRs 
67-71, but the effect of weight reduction through lifestyle intervention per se on kidney 
transplant outcomes, including “surrogates” such as acute rejection, remains undetermined. 
 
Firstly, Patel et al 72 reported that 4-months of intensive individualised dietary intervention 
immediately post transplant resulted in significant reduction in body weight and BMI.  
However, 8 months following cessation of dietary intervention, significant weight gain and 
increased BMI was observed.  These findings suggested that early intensive dietary advice 
and regular follow-up is effective in controlling weight gain in the first-year following 
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transplant, and dietary advice should be an important component of post-transplant 
management.  Also, continued dietetic input beyond the early stage may be beneficial for the 
durability of weight control.   
 
Moreover, Lopes et al 67 showed that the 6 months of American Heart Association (AHA) 
Step One Diet with individualised diet plan and monthly dietetic review significantly reduced 
body weight and body fat.  This was accompanied by a significant improvement in nutritional 
intake profile including reductions in calorie, dietary cholesterol, total lipids, saturated fats 
and monounsaturated fats.  Along with this, lipid profile also improved, including decreased 
total- and low-density lipoprotein (LDL) cholesterol, resulting in reduced CVD risk.           
 
Furthermore, Orazio et al 73 , by using the Transtheoretical Model of Health Behaviour 
Change to incorporate simple exercise advice and nutrition therapy (Mediterranean-style low 
glycaemic index diet), produced results that mirrors Lopes et al, where significant weight loss 
was observed among KTRs with abnormal glucose tolerance.  The progress was also 
complemented with significant improvement in dietary risk factors for CVD including 
reductions in intakes of energy, total fat and percentage saturated fat.  Improvement in other 
CVD risk factors was also evident, including reductions in triglycerides, total- and LDL- 
cholesterol.  Importantly, patients with >5% weight loss were associated with increased HDL 
cholesterol. 
 
Conversely, a study by Jezior et al 74 demonstrated that a weight reduction program 
comprised of 2 sessions with 6 months interval apart failed to achieve an overall weight 
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reduction.  Nevertheless, 27% of patients experienced weight loss following the program.  
The lack of success could be explained by the nature of this study where no dietary advice 
was given during the program.  At the first visit, patients were only given an evaluation of 
dietary intake followed by anthropometry assessment and a short description of the negative 
effects of obesity on post-transplant morbidity.  Six months later at the second visit, patients 
then received dietary advice based on the analysis of the first visit. 
 
In addition to dietetic intervention, increased physical activity level is an important lifestyle 
modification strategy for weight reduction.  Zelle et al 75 reported an association between 
increased physical activity level and reduced mortality in KTRs independent of waist 
circumference, muscle mass, triglyceride and insulin levels. 
 
Nutritional intervention vs pharmacological approach 
 
Dietary interventions have shown promising results in weight management when compared 
with findings from recent prospective controlled trials investigating steroid minimisation as 
an immunosuppressive strategy.  Woodle et al 52 demonstrated that patients on steroid 
avoidance protocol gained 2.6kg less weight compared to patients on 5mg maintenance 
steroid therapy.  Also, Vincenti et al 76 reported that patients on steroid avoidance protocol 
gained 1.0kg/m2 less BMI increment compared to patients on 5-10mg maintenance steroid 
therapy.  These results are rather unremarkable compared to the results from nutritional 
interventions shown in Table 3.  Importantly, both studies 52,76 using steroid minimisation 
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have shown an increase in acute transplant rejection, which raises concerns over the use of 
steroid minimisation as a strategy for weight management.    
 
Alternative strategies to weight management 
 
Generally, weight management has proven to be a difficult challenge, involving calorie 
reduction, increased physical activity, and behavioural modification.  Increasingly, 
pharmacological and surgical options are pursued to tackle the problem.  The use of anti-
obesity medications has not been exclusively studied in KTRs.  Sibutramine was associated 
with hypertension 77, Orlistat interfered with cyclosporine absorption decreasing its 
bioavailability 78, and Rimonabant treatment led to increased systemic exposure of 
Cyclosporin A as well as psychiatric complications in some patients 79.  Bariatric surgery 
yielded substantial weight loss in KTRs 39, and gastric bypass procedure has shown promise 
in selected KTRs, leading to reduction in cardiovascular co-morbidity 80. 
 
Future research on obesity in kidney transplantation  
 
Currently, the effect of pre-transplant obesity on patient- and graft- survival remains unclear.  
Also, clinical trials demonstrating the effects of intentional pre-transplant weight loss on 
subsequent patient- and graft- survival are lacking.  Given the well-established contributions 
of obesity to increased morbidity and mortality following transplantation, future research in 
this area should be channelled towards prospective interventional studies, aiming to evaluate 
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the impact of pre-transplant intentional weight loss through bariatric surgery, lifestyle 
modification, and behavioural intervention on short- and long- term outcomes of kidney 
transplantation. 
 
On the contrary, the adverse effect of obesity following transplantation is well-established.  
Nutritional intervention studies have shown promising results in achieving weight loss and 
improving risk factors for CVD, but lacked hard clinical endpoints e.g. risk of graft failure 
and mortality.  Future studies should concentrate on evaluating the effect of weight loss on 
long-term transplant outcomes.  Also, the role of visceral adiposity and its related adipose 
tissue cytokines have only received preliminary attention in kidney transplantation research.  
At present, there is a lack of pre-clinical data on this topic, thereby highlighting the need to 
develop experimental animal models of renal transplant with obesity in parallel to ongoing 
clinical studies.  This will not only aid in dissecting the pathophysiology of obesity in renal 
transplants, but also paving the way for possible interventional studies in the future.  In 
addition, further clinical research should assess the effect of varying adipokines on 
inflammation and the associated effects on graft failure and mortality.  Similarly, the role of 




In summary, obesity is common both at the time of transplantation and following 
transplantation.  While the implication of pre-transplant obesity on kidney transplant 
outcomes remains unclear, post-transplant obesity is a significant risk factor for graft failure 
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and mortality.  Obesity intervention post-transplantation focusing on nutritional therapy has 
shown encouraging results in weight management, but the impact on long term outcomes has 
not been demonstrated.  There is now emerging data signifying the relevance and benefit of 
nutritional intervention in KTRs.  It is therefore important that future research should focus 
on conducting nutritional intervention studies aiming to improve kidney transplant outcomes 




This review article is the first to not only highlight the role of nutritional intervention and the 
impact of sarcopenia on kidney transplant outcomes, but to illustrate the complex 
pathophysiology of obesity in this patient population.  Future research should focus on 
conducting prospective studies of nutritional intervention, aiming to evaluate the impact on 
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 Table 1:  Summary of studies showing the impact of pre-transplant obesity on kidney transplant outcomes 
Study Sample 
Size 







Impact on Kidney Transplant 
Outcomes 
Lynch et al 
(2009) 
869 Retrospective  
 
BMI  Surgical site infection post-transplantation 
 3-year graft survival 
 3-year patient survival 
 
 Prevalence of surgical site infection is higher among obese KTRs. 
 Obesity had no independent effect on 3-year graft- and patient- survival 
outcomes.  
 
 Impact on short-term outcome 




493 Retrospective  
 
BMI  Superficial wound breakdown  
 Complete wound dehiscence 
 Wound infections 
 Other post-operative complications 
 Hospitalization rates 
 Delayed graft function 
 Acute rejection episodes 
 5-year graft survival 
 5-year patient survival 
 
 Raised BMI predicts wound breakdown. 
 BMI does not predict other post-operative complications, hospitalization 
rates, 5-year graft- and patient- survival. 
 Impact on short-term outcome 




173 Retrospective  
 
BMI  Wound infections 
 Other surgical complications 
 3-year graft survival 
 3-year patient survival 
 
 Patients with BMI>30 kg/m2 have increased wound infections. 
 No difference in other surgical complications, 3-year graft- and patient- 
survival between different BMI categories. 
 
 Impact on short-term outcome 
 No impact on long-term 
outcomes 
Massarweh 
et al (2005) 
193 Retrospective BMI 
 
 
 Graft-loss (total loss of graft function or patient 
death with a functioning graft) with mean follow-
up time of 24 months 
 Acute rejection rates 
 Post-transplant surgical complications 
 
 Patients with BMI≥30kg/m2 had increased incidence of post-transplant 
surgical complications. 
 No difference in acute rejection rates, long-term mortality and risk of graft 
failure between patients with BMI<30kg/m2 and ≥30kg/m2. 
 Impact on short-term outcome 
 No impact on long-term 
outcomes 
Hoogeveen 
et al (2011) 
1,810 Prospective BMI  Patient survival in a 20-year follow-up study with 
median follow-up time of 8.3 years 
 Graft-survival in a 20-year follow-up study with 
median follow-up time of 8.3 years 
 
 Obesity (BMI>30 kg/m2) is a risk factor for both patient mortality and graft 
failure independent of other cardiovascular risk factors. 
 Obesity (BMI>30 kg/m2) increased the risk of death and graft failure by 20-
40% compared with normal BMI. 
 A high BMI (>30 kg/m2) post-transplantation was more strongly related to 
death and graft failure compared with pre-transplant obesity. 
 





 51,927 Retrospective BMI  Primary study end-points were graft- and patient- 
survival for up to 10 years post-transplant. 
 Secondary study end-points were death censored 
graft survival, chronic allograft failure, delayed 
graft function, and acute rejection. 
 
 Very high and very low BMI were associated with worse patient- and graft- 
survival. 
 Very high and very low BMI were associated with death censored graft 
failure and chronic allograft failure. 
 Elevated BMI was associated with increased risk of delayed graft function. 
 No association between BMI and acute rejection. 
 
 Impact on short-term outcome 
 Impact on long-term outcomes 
Sancho et al 
(2007) 
337 Retrospective BMI  Graft survival with a mean follow-up of 54 
months 
 Compared to normal weight patients (BMI<25kg/m2), overweight patients 
(BMI>30kg/m2) displayed higher incidence of hypertension, left-ventricular 
 Impact on graft survival 
 Patient survival was lower in 
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  Patient survival with a mean follow-up of 54 
months 
 Acute rejection episodes 
 Post-transplant co-morbidity 
 
hypertrophy, dyslipidemia, acute tubular necrosis, acute rejection episodes, 
post-transplant diabetes. 
 No difference in graft survival between BMI categories. 
 Compared to normal weight patients (BMI<25kg/m2), patient survival was 
lower in overweight patients (BMI>30kg/m2). 
 
overweight patients 
Gore et al 
(2006) 
27,377 Retrospective BMI  Intermediate measures of graft outcome 
 Overall graft survival for up to 6 years post 
transplantation 
 Morbid obesity (BMI≥35kg/m2) was independently associated with 
increased risk of delayed graft function, prolonged hospitalization, and acute 
rejection in the post-operative period. 
 Morbid obesity (BMI≥35kg/m2) decreased overall graft survival. 
 
 Impact on short-term 
outcomes. 
 Impact on long-term 
outcomes. 
Schwarznau 
et al (2008) 
 
81 Retrospective BMI  Graft loss within the first year after kidney 
transplant 
 Increased BMI was in independent risk factor for graft loss within the first 
year post transplant 





405 Retrospective BMI  7-year graft survival 
 7-year patient survival 
 BMI>25kg/m2 conferred a 2-fold relative risk of long-term graft loss and 
patient death. 
 The 7-year actuarial graft survival was higher among the non-obese KTRs 
(BMI≤25kg/m2) compared to the obese KTRs (BMI>25kg/m2), 88% vs 
72%. 
 The 7-year actuarial patient survival was higher among the non-obese 
KTRs (BMI≤25kg/m2) compared to the obese KTRs (BMI>25kg/m2), 92% 
vs 81%. 
 





833 Retrospective BMI  1- and 5- year graft survival 
 1- and 5- year patient survival 
 Higher incidence of delayed graft function was found in overweight KTRs 
(BMI between 25.0kg/m2 and 29.9kg/m2) and obese KTRs 
(BMI≥30.0kg/m2). 
 Higher incidence of post-transplant diabetes mellitus was found in obese 
KTRs (BMI ≥30.0kg/m2). 
 Death with a functioning graft was less common among obese KTRs (BMI ≥ 
30.0kg/m2) compared to normal weight KTRs (BMI between 25.0 kg/m2 and 
29.9kg/m2) and overweight KTRs (BMI ≥30.0kg/m2). 
 No difference in 1-year and 5-year graft- and patient- survival between 
different BMI categories (<25.0kg/m2, 25.0-29.9kg/m2, and ≥30.0kg/m2). 
 
 Impact on short-term outcome. 
 No impact on long-term 
outcomes. 
Marks et al 
(2004) 
 
247 Retrospective BMI  3-year graft survival 
 3-year patient survival 
 Post-operative complications 
 Rejection episodes 
 Length of hospital stay 
 Readmission rate within the first 6 months post-
transplant 
 
 No difference in actuarial patient- and graft- survival rate for the first 3 years 
after transplant between non-obese and morbidly obese KTRs. 
 Length of hospital stay, number of readmissions within the first 6 months 
post-transplant, and the number of major wound complications were greater 
for morbidly obese KTRs compared with non-obese KTRs. 
 Impact on short-term outcome 
 No impact on long-term 
outcomes 
Yamamoto 
et al (2002) 
 
56 Retrospective BMI  1-, 3- and 5- year graft survival 
 1-, 3- and 5- year patient survival 
 Delayed graft function 
 Acute rejection 
 
 Obesity (BMI>30kg/m2) is not a risk factor for delayed graft function, acute 
rejection, and 1-year graft survival. 
 Decreased 3-year and 5-year graft survival trend was observed in obese 
KTRs (BMI>30kg/m2). 
 No difference in patient survival between obese and non-obese KTRs at 1-, 
2-and 5- year post-transplant. 
 
 No impact on short-term 
outcomes. 
 Impact on medium- and long- 
term graft survival 
 No impact on patient survival 
in short-, medium, and long- 
term. 
 
Streja et al 10,090 Retrospective BMI  Graft survival up to 6 years post-transplant  Up to 6 years post-transplantation, obesity (BMI>30kg/m2) was not  Impact on long-term graft loss. 
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(2011) 
 
 Patient survival up to 6 years post-transplant 
 
associated with mortality, although it showed a trend towards higher graft 
loss. 
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Table 2:  Summary of studies showing the impact of steroids on weight gain and body composition 
Study Sample Size Study Type Exposure Variable Study Protocol Key Findings in relation to Weight Gain and Body Composition 
 
Ratcliffe et al (1996) 100 Randomised 
controlled trial of 
steroid withdrawal 
 
Body weight KTRs were randomised either to reduce 
prednisolone treatment to zero over 4 
months or to maintain their triple 
immunosuppression unchanged. 
 
 Steroid withdrawal was associated with a significant reduction in body 
weight, whereas slight weight increase was observed in the control group. 
 
van den Ham et al 
(2003) 
 
123 Longitudinal study 
with a follow-up 
period of 5 years 
Body weight KTRs on either steroid- or steroid-free 
immunosuppression therapy. 
 
 Weight gain occurs in all KTRs, no difference in weight gain was found 
between KTRs on steroid- or steroid-free immunosuppression therapy. 
 Within the first year post-transplant, increase in body weight was related 
neither to maintenance- nor cumulative steroid dose. 
 After the first year post-transplant, cumulative steroid dose was positively 
related weight gain. 
 
Rogers et al (2005) 301 Prospective study with 
a follow-up period of 
12 months 
 
Body weight KTRs on either chronic corticosteroid 
therapy (CCST) or corticosteroid 
withdrawal (CSWD) within 7-day post-
transplant. 
 
 Weight gain was significantly higher in KTRs on CCST at 3, 6, and 12 
months post-transplant. 
 Early CSWD minimizes weight gain in KTRs. 
 
Woodle et al (2008) 
 




Body weight KTS on either early corticosteroid 
withdrawal (CSWD) or chronic low 
dose corticosteroid therapy (CCS). 
 CSWD lead to significantly lower weight gain compared to CCS. 
Johnson et al (1993) 115 Retrospective study  




Body Weight Potential factors (including cumulative 
steroid dose) influencing post-
transplantation weight gain were 
assessed. 
 Weight gain did not correlate with cumulative steroid dose. 
Elster et al (2008) 95 Retrospective study 





KTRs who received either lymphocyte 
depletion-based steroid sparing or 
traditional immunosuppressive therapy 
that included steroids for maintenance 
immunosuppression. 
 
 Regardless of immunosuppression therapy, BMI and body weight 
increased post-transplant in all KTRs. 
 
van den Ham (2000) 
 
77 Cross-sectional study Body composition 
 
KTRs on either 0-, 5-, and 10- mg 
maintenance steroid therapy. 
 
 No significant differences in fat mass, lean body mass, and body fat 
distribution between KTRs on 0-, 5-, and 10-mg maintenance steroid 
therapy. 
 No significant relationships between cumulative steroid dosage and body 
composition and body fat distribution parameters in KTRs. 
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Table 3:  Comparison between nutritional intervention and steroid minimisation 
protocols on weight changes 
Study 
 
Intervention Magnitude of Weight Changes 
Patel et al (1998) 
 
4-month individualised dietary 
advice immediately post 
transplant with regular follow-up 
compared with no dietary advice 
and follow-up 
 
Dietetic intervention resulted in 
5kg less weight gain compared to 
no dietetic intervention 
Lopes et al (1999) 
 
6-month American Heart 
Association (AHA) Step One 
Diet with individualised diet 
plan and monthly dietetic review 
 
Significant reduction of 3kg 
Orazio et al (2011) 
 
Transtheoretical Model of 
Health Behaviour Change 
incorporating simple exercise 
advice and nutrition therapy 
(Mediterranean-style low 
glycaemic index diet) 
 
Mean weight reduction not 
reported, but patients 
underweight lifestyle 
intervention resulted in 3.8% 
weight loss 
Jezior et al (2007) 
 
Weight reduction program 
comprised of 2 sessions with 6 
months interval apart 
 
Mean weight unchanged, but 
27% of patients enrolled in 
weight reduction program 
experienced weight loss 
 
Woodle et al (2008) 
 
Steroid cessation by day 7 post 
transplantation compared with 
5mg steroid maintenance 
 
Steroid cessation resulted in 
2.6kg less weight gain compared 
to 5mg steroid maintenance 
therapy 
 




compared with 5-10mg steroid 
maintenance therapy 
 
Mean weight reduction not 
reported, but mean BMI 
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